Evidence map›Paper›PMID 37656245›Full record

ReviewJournal of cancer research and clinical oncology2023

Artificial intelligence in breast cancer: application and future perspectives.

Shuixin Yan, Jiadi Li, Weizhu Wu

Abstract readReview
In one paragraph

Review in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shuixin YanThe Affiliated Lihuili Hospital of Ningbo University, Ningbo, 315000, Zhejiang, China.
Jiadi LiThe Affiliated Lihuili Hospital of Ningbo University, Ningbo, 315000, Zhejiang, China.
Weizhu WuThe Affiliated Lihuili Hospital of Ningbo University, Ningbo, 315000, Zhejiang, China. wuweizhu1128@163.com.

Funding

The Fourth Round of Ningbo City's Key Medical Disciplines Development Plan 2022-F03
6 · The paper itself

Abstract

Breast cancer is one of the most common cancers and is one of the leading causes of cancer-related deaths in women worldwide. Early diagnosis and treatment are the key for a favorable prognosis. The application of artificial intelligence technology in the medical field is increasingly extensive, including image analysis, automated diagnosis, intelligent pharmaceutical system, personalized treatment and so on. AI-based breast cancer imaging, pathology and adjuvant therapy technology cannot only reduce the workload of clinicians, but also continuously improve the accuracy and sensitivity of breast cancer diagnosis and treatment. This paper reviews the application of AI in breast cancer, as well as looks ahead and poses challenges to the future development of AI for breast cancer detection and therapeutic, so as to provide ideas for future research.

Indexed as

Breast NeoplasmsArtificial IntelligenceCombined Modality TherapyFemaleHumansImage Processing, Computer-AssistedArtificial intelligenceBreast cancerDiagnosisTreatment

Identifiers

PMID37656245
PMCPMC11797688

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.